^
Association details:
| Biomarker: | HRAS mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.
Published date:
05/19/2021
Excerpt:
Selumetinib did not result in tumor regression in this cohort of children and young adults with treatment-refractory tumors with activating MAPK pathway alterations.
DOI:
10.1200/JCO.2021.39.15_suppl.10008
Trial ID:
